Rockefeller Capital Management
TVRD

Rockefeller Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

Rockefeller Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4
Closed -$156 – 4881
2025
Q3 		$156 Buy
+4
New +$114 ﹤0.01% 4356
2025
Q1 		– Sell
-51,906
Closed -$953K – 1751
2024
Q4 		$953K Buy
+51,906
New +$565K ﹤0.01% 1265
2023
Q1 		– Sell
-29
Closed -$11K – 3970
2022
Q4 		$11K Sell
29
-37
-56% -$14.1K ﹤0.01% 3058
2022
Q3 		$22K Sell
66
-5
-7% -$1.81K ﹤0.01% 2736
2022
Q2 		$23K Buy
71
+6
+9% +$2.1K ﹤0.01% 2676
2022
Q1 		$28K Hold
65
– – ﹤0.01% 2586
2021
Q4 		$28K Hold
65
– – ﹤0.01% 2483
2021
Q3 		$36K Buy
65
+22
+51% +$11K ﹤0.01% 2308
2021
Q2 		$21K Buy
43
+15
+54% +$9.51K ﹤0.01% 2474
2021
Q1 		$21K Sell
28
-83
-75% -$56.8K ﹤0.01% 2268
2020
Q4 		$60K Sell
111
-28
-20% -$14.7K ﹤0.01% 1620
2020
Q3 		$63K Hold
139
– – ﹤0.01% 1431
2020
Q2 		$86K Hold
139
– – ﹤0.01% 1222
2020
Q1 		$66K Sell
139
-111
-44% -$60.3K ﹤0.01% 1156
2019
Q4 		$145K Hold
250
– – ﹤0.01% 851
2019
Q3 		$165K Buy
+250
New +$208K ﹤0.01% 669

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $361M AUM 18% 1-Year Est. Return

Rockefeller Capital Management's TVRD Position: Q4 2025 in Review

Rockefeller Capital Management sold out of Tvardi Therapeutics (TVRD) in Q4 2025, closing a stake of 4 shares — an estimated $156 sold.

Rockefeller Capital Management first reported a position in TVRD in Q3 2019 and held it in 16 quarters. The position peaked at $953K in Q4 2024. 67 funds tracked by Wall St. Rank hold TVRD as of Q4 2025.

  • Rockefeller Capital Management reported no remaining Tvardi Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Rockefeller Capital Management sold 4 Tvardi Therapeutics shares in Q4 2025, an estimated $156.
  • Rockefeller Capital Management first reported a position in Tvardi Therapeutics in Q3 2019 and held it in 16 quarters.
  • Rockefeller Capital Management's Tvardi Therapeutics position peaked at $953K in Q4 2024.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2025.

Based on Rockefeller Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.